Eli Lilly (LLY) announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares of common stock of Point Biopharma (PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. The tender offer, which was previously scheduled to expire at 5:00 p.m., Eastern time, on November 16 has been extended until 5:00 p.m., Eastern time, on December 1, unless the tender offer is further extended or earlier terminated, in order for the parties to satisfy the minimum tender condition. All regulatory approvals necessary for the consummation of the transaction have been obtained.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LLY:
- Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023
- Cantor biotech/biopharma analysts hold analyst/industry conference call
- Eli Lilly (NYSE:LLY) Looks to Grab a Bite of the Obesity Market Pie
- Eli Lilly to invest ‘single-digit billion’ in new German plant, Reuters reports
- Eli Lilly receives NRC consent regarding proposed Point Biopharma acquisition